Breast cancer is the most common cancer, and the second cause of cancer-related deaths (after lung cancer) among women. Developing tumor metastasis and invasion is the most important cause of death in breast cancer patients. Several key factors participate in breast cancer metastasis including long noncoding RNAs (lncRNAs). lncRNAs are a category of cellular RNAs that are longer than 200 nucleotides in length. Accumulating evidence suggests that lncRNAs have the potential to be promising diagnostic, prognostic biomarkers and therapeutic targets in breast cancer. Understanding the role of lncRNAs and their mechanisms of functions might help to further discovery of breast cancer biological characteristics. In this review, we discuss physiological functions, epigenetic regulation, transcriptional regulation of lncRNAs, and their important role in tumor progression and metastasis. Some lncRNAs function as oncogenes and some function as tumor suppressors. Interestingly, recent reports depict that hypomethylation of promoters of lncRNAs play a pivotal role in cancer progression, suggesting the importance of epigenetic regulation. Furthermore, we discuss the role of lncRNAs in exosomes and their function in drug resistance, and therapeutic importance of exosomal lncRNAs in cancer biology. In summary, lncRNAs have a great potential to consider them as novel prognostic biomarkers as well as new therapeutic targets in breast cancer ;,: 1234567890();,:
Introduction
In humans, although 70% of the genome is transcribed to RNA, only about 2% of these transcripts are translated into proteins [1, 2] . The rest of the transcripts are defined as noncoding RNAs, which can be divided into two main groups; (1) short noncoding RNAs including microRNAs (miRNAs), small interfering RNAs (siRNAs), P-elementinduced wimpy testis-interacting RNA and small nucleolar RNAs (snoRNAs); and (2), long noncoding RNAs (lncRNAs) [2] . Among these, short noncoding RNAs are mainly considered as negative regulators of gene expression; while lncRNAs are a wide heterogeneous group that has not been well studied so far [3] . Many of these lncRNAs are shown by genome-wide association studies and implicated in a variety of human diseases including cancers [1, 3] . lncRNAs are defined as transcripts with a length of more than 200 bp and lack of open reading frames. lncRNAs share several common features with protein coding sequences, including the existence of unique epigenetic marks such as trimethylation on lysine 4 of histone H3 at promoter site and trimethylation on lysine 36 of histone H3 along the transcribed region. Their sequence also possesses introns that can be transcribed by RNA polymerase ΙΙ. In addition, their transcripts have a poly A tail similar to mRNAs, in many but not all; and the transcripts undergo splicing process [1] [2] [3] as well.
Overview of lncRNAs classification, function, and regulation
Classification of lncRNAs lncRNAs are classified into many different types based on their genomic structure and origin. Some of the lncRNAs are pseudogenes that contain mutations, making them noncoding sequences. Many of the lncRNA coding sequences overlap with coding genes, entirely or partially. It is estimated that about 20% of human transcriptome forms sense-antisense pairs [3] . Overlapping lncRNAs make up three categories. The first group is Sense lncRNAs. These lncRNA genes overlap with one or more exons of another gene and are transcribed in the same direction as the coding gene. The second group is Antisense lncRNA and their sequence overlaps with one or more exons of a coding gene in the opposite direction. Intronic lncRNAs are the third group, which are located within the introns of proteincoding genes. Interestingly, some lncRNAs are located within the coding genes. These include two categories, the first group includes bidirectional lncRNAs that exist in proximity of coding genes, but on the opposite DNA strand. The second group is long intergenic ncRNAs (lincRNAs), which are derived from a genomic sequence between the two independent coding genes. An overview of lncRNAs classification is shown in Fig. 1 [1, 3] . Most of the lncRNAs are reported to be originated from intergenic regions and also from the upstream and antisense strand of coding gene promoters [4] . Moreover, recent studies suggested that circular RNAs are common forms of transcribed RNAs and they are believed to be mainly noncoding transcripts. Due to their resistance to exonucleases, they are considered as very stable RNAs [2, 3] .
Physiological functions of lncRNAs
It is estimated that 60,000-100,000 lncRNA genes exist in humans [5, 6] , however, only about 200 of them are well studied. lncRNA expression is mainly tissue specific; this suggests their possible functional role in physiological and biological processes. [1] . Accordingly, it has been shown that lncRNAs are engaged in many different biological processes within the cell and exert specific functions in different stages of cell regulation [7] . Recent studies have shown that lncRNAs are important regulators of cancerrelated cellular pathways [8] . lncRNAs play key roles at the epigenetic level, through interacting with chromatin modifying complexes or by regulating at the transcriptional level through interactions with DNA regulatory elements. Other Fig. 1 Classification of lncRNAs, based on their genomic origin, in relation with protein coding genes; a sense, b antisense, c intronic, d bidirectional, and e intergenic lncRNAs lncRNAs regulate gene expression through interfering with posttranscriptional nuclear machinery [1, 8, 9] . This diversity in lncRNAs functions is probably due to the versatile nature of RNA molecules. RNAs are able to construct a number of secondary structures, and thus they are able to bind and interact with a vast range of highly specific substrates [7] . Moreover, noncoding RNAs are highly dynamic transcripts and their levels can rapidly change in order to efficiently regulate the gene expression [3] . Furthermore, based on three-dimensional approaches, lncRNAs are divided into cis-acting and trans-acting categories [5, 8] . The cis-acting lncRNAs functioning is limited to the same chromosome of their origin and they just affect a few genes locally; however, trans-acting lncRNAs tend to regulate a wider range of genes on neighboring or distant chromosomes [1] . Many of epigenetic-related lncRNAs are defined as cis-regulating; although some function in a trans-acting manner [3] .
Local regulation of chromatin structure or gene expression
Cis-acting lncRNAs utilize three mechanisms: first, lncRNAs directly recruit regulatory complexes to the neighboring gene locus; second, they regulate transcription or splicing process which make them regulatory lncRNAs; and finally, the cis-regulation of genes may be completely independent of lncRNAs, only through DNA elements embedded within their promoter or gene locus. X-inactive specific transcript (XIST) is the most well-known example of cis-acting lncRNAs, which participates in X-chromosome inactivation [5, 8] .
Regulation of cellular functions in a trans-acting manner
Several lncRNAs regulate cellular organization where their function is distinct from their origin of chromosomal locus [8] .They can regulate in three different ways. First, lncRNAs regulate gene expression through interaction with chromatin complexes or binding directly with DNA [8] . Among the first identified lncRNAs, HOTAIR belongs to this group. Second, lncRNAs also organize nuclear architecture by serving as scaffolds [5] . Finally, lncRNAs control intracellular trafficking, cell-cell signaling and regulation of proteins activity through interplay with cellular macromolecules such as protein complexes and other RNAs [7, 8, 10, 11] .
Epigenetic regulation of lncRNAs
Expression pattern of genes in different cells is controlled by epigenetic modifiers, such as regulators of histone modifications, DNA methylation and chromosomal architecture (Figs. 2 and 3) [12, 13] . Histone methyltransferases and polycomb repressive complexes (PRCs) have been well studied [6] . PRCs are well-known nucleoprotein complexes that promote gene silencing through modification of the structure of chromatin. Expression of tumor suppressor genes is inhibited by these chromatin modifiers. PRC2 is a well-characterized histone methyltransferase, required for gene silencing [13, 14] . lncRNAs are recognized as major RNA components of PRCs. About 20% of lncRNAs are reported to interact with PRCs. They have an essential role in cancer progression due to their cross-talk with different epigenetic factors, mainly by silencing tumor suppressor genes [1] . lncRNAs, such as ANRIL, HOTAIR, H19, and XIST, repress gene transcription by recruiting protein complexes, such as histone-modifiers and chromatin remodeling complexes (Table 1) [1, 6] .
lncRNA HOTAIR is overexpressed in metastatic breast carcinomas [15] , and is defined as a scaffold for recruitment of PRC2 and LSD1 (lysine-specific demethylase 1A) [1] , which is known to regulate histone methylation status and chromatin modification (Figs. 2 and 3) [3, 16] . Furthermore, the stability of the enhancer of zeste homolog (EZH2), a functional component of PRC2, is regulated by antidifferentiation noncoding RNA (ANCR) lncRNA, which suppresses invasion and metastasis in breast cancer [17] .
Transcriptional regulation of lncRNAs

Transient lncRNAs within active enhancer regions
Several studies indicate that lncRNAs can directly regulate gene expression affecting enhancer sequences of the gene promoter. Enhancers are often far away from the transcriptional start site and recruit tissue-specific transcription factors (TFs) to the promoter of a given gene. Some lncRNAs, are enhancer RNAs (eRNAs), which can be bidirectionally transcribed from the enhancer regions in the genome, and the expression of these eRNAs is concordantly changed with the neighboring coding genes [1, 14] . It has been thought that eRNAs might participate in chromatin remodeling; therefore, they assist in stability of DNA-loop constructed in the proximity of target genes [3, 14] .
Independent lncRNAs with enhancer-like activity
Also, there are some lncRNAs that can directly serve as enhancers. These lncRNAs called activating ncRNAs and include a class of independent ncRNAs located in more than 1 kb upstream of the coding genes; therefore, they confer similar expression pattern like their neighboring genes. Although ncRNAs can be polyadenylated, spliced and transcribed like mRNAs; they can also function similar to eRNAs, forming a chromatin bridge between coding gene locus and enhancer-like elements [1, 3] .
Posttranscriptional regulation of lncRNAs
Another regulatory mechanism of lncRNAs in gene expression is posttranscriptional mRNA regulation [7] . lncRNAs as regulators of mRNA processing lncRNAs regulate mRNA processing in the nucleus [6] . A typical example is shown in Fig. 4 , where nuclear body paraspeckles that contain RNAs and RNA processingrelated proteins [5] . CTN-RNA is an 8 kb nuclear RNA, localized in paraspeckles; which is a peer of mCAT2, a protein coding gene. CTN-RNA is stocked within paraspeckles when cell does not need mCAT2 mRNA. It has been shown that lncRNAs, such as NEAT1 (nuclear-enriched abundant transcript 1), make up the RNA components of paraspeckles, which serve as scaffolds. Accordingly, it can be concluded that different lncRNAs cooperate to regulate mRNA processing [1] . Interestingly, there is another well-characterized lncRNA, MALAT1 (NEAT2), which is located adjacent to NEAT1 gene locus. MALAT1 overexpression is associated with breast carcinomas [18] , and it is localized to the nuclear speckles to regulate the splicing machinery; and it is one of the best examples of lncRNAs that regulate mRNA alternative splicing process. [5, 6] . In addition, lncRNA MIAT (myocardial infarction-associated transcript) regulates alternative splicing through Gomafu nuclear body formation [6] .
lncRNA and microRNA interactions miRNAs play a key role in lncRNA biology through establishing networks and interactions between miRNAs and lncRNAs. miRNAs are mainly considered as negative regulators of gene expression via binding to their mRNA targets [3] . Similar to miRNAs, lncRNAs play important role in RNA-RNA interactions to regulate gene expression [1] .
lncRNAs as a source of miRNAs
As shown in Fig. 5 , lncRNAs serve as a source of miRNA biogenesis. Most of miRNAs reside within their host's introns and a few of them are located within the exons of lncRNAs. One good example of this category is miR-31, a key regulatory RNA in metastasis and invasion of breast cancer [19] , which is embedded within an intron of the lncRNA LOC554202. miR-31 is downregulated in breast cancer via DNA-methylation of its promoter region [3] . Fig. 3 lncRNA, a biochemically versatile polymer; posttranscriptional level, a mRNA processing: Antisense lncRNAs can modulate either splicing patterns or RNA editing process of their target pre-mRNAs. b Regulatory ncRNAs: Many lncRNA genes possess miRNA sequences (red boxes) within themselves; either within lncRNA exons (yellow boxes) or introns (lines). Moreover, miRNAs can be generated by their independent transcriptional units on genome. These three pathways lead to different primary-miRNA formation; but all of them have the same consequence, resulting in mature miRNA biogenesis. c RNA-RNA interactions: The ceRNA (competing endogenous RNA) hypothesis: miRNAs are mainly considered as inhibitors of gene expression. They bind to their target mRNAs through MRE (miRNA response element, showed by ovals) sequences, which are ordinary within mRNA's 3′UTR (untranslated region). These MREs are also present within other types of RNAs, such as lncRNAs, circRNAs, pseudogenes, and independently transcribed mRNA 3′UTR. lncRNAs and circRNAs may contain multiple MREs for different miRNAs (different-colored ovals). All these MRE-containing ncRNAs are potential competitors for mRNAs in binding and sequestering miR-NAs (called ceRNA); and thus, potentially upregulate gene expression. d Interaction with protein complexes. lncRNAs can play role in mRNA's fate by modulating binding of RBPs (RNA-binding protein) and thus affect their stability [20] . e mRNA's fate regulation: Antisense lncRNAs can affect target mRNAs translation and stability in cytoplasm [17] lncRNAs as miRNA's decoys: competing endogenous RNAs (ceRNAs) lncRNAs also function as negative regulators of miRNAs. As shown in Fig. 6 , lncRNAs can bind to miRNAs and sequester them in the cell, inhibiting their regulatory effects on gene expression [3, 20] . For example, H19 lncRNA, which hosts miR-675 within its first intron, has been shown to inhibit miR-675, suggesting a ceRNA role of H19 lncRNA. In fact, it has been shown that H19 acts as a ceRNA for several miRNAs [3] . The oncogenic role of H19 lncRNA in breast cancer invasion and metastasis is well characterized in previous studies [21] . XIST is another wellknown lncRNA that suppresses breast cancer invasion through direct targeting of miR-155 [22] .
lncRNAs as miRNA-independent regulators of mRNA
It is possible that both miRNAs and lncRNAs regulate several mRNAs at the same time. In addition, a given mRNA can be targeted by a number of lncRNAs [1] . lncRNAs may either suppress mRNA translation; or lead to mRNA degradation. For example, lincRNA-p21 binds to its mRNA targets and induce polysome displacing that results in suppression of translation [1] . Moreover, lncRNAs are able to degrade mRNAs as well [3] . lncRNAs with Alu elements, can promote mRNA decay by binding to their 3′ UTR. This base pairing provides a binding site for STAU1, an RNA degradation-protein, and results in RNA degradation [1, 3, 7] . Another mechanism by which lncRNAs regulate mRNA translation is through modulating mRNA stability. lncRNAs can form sense or antisense pairs with their target mRNAs [1] . A representative of this group is nuclear-enriched lncRNA antisense to mouse ubiquitin carboxy-terminal hydrolase L1 (Uchl1). Antisense-lncRNA increases the UCHL1 protein synthesis by pairing with the sense target mRNA [23] . These data show that lncRNAs are essential regulators of gene expression through different mechanisms at different levels, and importantly, aberrant expression of lncRNAs promote the initiation and progression of tumors [11] .
The role of lncRNAs in cancer
Several studies indicated that lncRNAs play an essential role in different stages of cancer development and progression. Aberrant expression of lncRNAs is correlated with tumorigenesis [24] . Thus, lncRNAs can function as tumor suppressor or oncogenic lncRNAs.
Tumor suppressor lncRNAs
P53, a transcriptional factor that regulates the expression of downstream target genes involved in cell stress, DNA damage, and apoptosis. lncRNAs can be directly or indirectly regulated by P53 [25] . The lincRNA-p21 is a target for P53 and it induces apoptosis. lincRNA-p21 interacts with heterogeneous nuclear ribonucleoprotein K (HNRNPK) and potentiate HNRNPK to bind the promoter of its target genes that are involved in promoting apoptosis and cell death [25] . PANDAR is a tumor suppressor lncRNA that regulates P53-dependent apoptosis [26] . In addition, LINC-PINT lncRNA is transcriptionally regulated by P53, and promotes cell cycle arrest and apoptosis through epigenetic repression of its downstream target genes [27] . LOC285194 is another lncRNA that functions as a tumor suppressor, and is a direct target of p53. [28] . XIST lncRNA participates in Xchromosome inactivation in females [29] . XIST gene is located on the long arm of X-chromosome, and its RNA is 17 Kb in length [29] . Downregulation of XIST has been Under cell stress, mCAT mRNA is immediately needed. Thus, CTN-RNA is released from paraspeckles and transferred and spliced in cytoplasm in order to increase mCAT mRNA level reported in breast, cervical, and ovarian cancers and functions as a tumor suppressor in these malignancies [30] . GAS5 (Growth arrest-specific 5) is another tumor suppressor lncRNA that regulates cell proliferation, growth arrest, and apoptosis [31] . Reduced expression of GAS5 is observed in many cancers including breast, colorectal, prostate, and lung [31] . CTD903 is a tumor suppressor lncRNA and inhibits epithelial-mesenchymal transition (EMT) [32] . Furthermore, TUSC7 lncRNA (Tumor suppressor candidate 7) is involved in many cellular processes such as transcription and regulation of miRNAs [33] . Downregulation of MALAT1 has been reported in breast cancer and results in promoting of EMT and metastasis in breast cancer [34] . Interestingly, lncRNAs can function differently in distinct gene expression background. For example, we recently showed that the Nischarin (a well characterized tumor suppressor protein) expression is an important factor in determining how MALAT1 activity is governed in breast cancer. MALAT1 knockout (KO) in low Nischarin expression background had a limited effect on cell functions, while MALAT1 KO in cells with high levels of Nischarin expression led to significant increase in cell proliferation and migration [35] .
Oncogenic lncRNAs
Oncogenic lncRNAs are associated with tumorigenesis and promote cancer development and progression. Several [36] . HOTAIR is an oncogenic lncRNA that promotes metastasis and invasion by employing PCR2 and promoting epigenetic modifications [16] . Upregulation of HOTAIR induces EMT and angiogenesis in breast cancer [37] . ANRIL (antisense noncoding RNA in INK4 locus) induces tumor invasion and progression via interacting with polycomb proteins and participating in epigenetic silencing of tumor suppressor genes such as P15 and P16 [38] . Furthermore, NEAT1 lncRNA has been reported as an oncogene in breast tumors, endometrial carcinoma and human osteosarcoma cells [39] [40] [41] . In non-small cell lung cancer (NSCLC), NEAT1 confers its oncogenic role by regulating the Wnt/β-catenin signaling pathway [42] . Focally amplified lncRNA on chromosome 1, represses the expression of P21 and its expression has been associated with several cancers [43] . Breast cancer antiestrogen resistance 4 lncRNA induces metastasis and antiestrogen resistance in breast cancer cells [44] . Moreover, steroid receptor RNA activator lncRNA is a coactivator of steroid receptor, and its overexpression has been reported in breast cancer [45] . BANCR (BRAF-activated noncoding RNA) lncRNA promotes cell invasion and metastasis in several cancers including gastric, breast, endometrial cancer, and hepatocellular carcinoma (HCC) [46, 47] . Overexpression of AFAP1-AS1 (actin filament associated protein 1 antisense RNA1), an oncogenic lncRNA has been reported in lung cancer, esophageal adenocarcinoma and HCC. AFAP1-AS1 increases the invasion and metastasis ability of tumors through regulation of actin filament integrity [48] [49] [50] . It is tempting to speculate that the suppression of lncRNAs may be helpful in developing novel therapies.
lncRNAs utilize different mechanisms to induce invasion and metastasis of breast cancer
Breast cancer metastatic cells invade a complex route from the primary tumor to metastasis during which they permanently need to adopt to hostile environments. Thus, tumor cells must undergo essential alterations to overcome the barriers and gain the characteristics needed for invasion to distant organs. Dysregulation of lncRNAs is a common feature of metastatic breast cancer cells [51] .
lncRNAs promote invasion and metastasis of breast cancer cells via inducing EMT
During metastasis, tumor cells transit from differentiated to undifferentiated phenotypes, and EMT inducing factors are crucial mediators of this plasticity which favors the progression of the invasion metastatic cascade [52] . HOXA11-AS has a crucial role in breast cancer metastasis, and its expression increases breast cancer growth. Moreover, inhibition of HOXA11-AS with specific siRNA resulted in the suppression of cell migration and invasion through the regulation of EMT factors such as E-cadherin, N-cadherin and vimentin [53] . lncRNA NEAT1 overexpression is associated with tumor size and metastasis in breast cancer. The inhibition of NEAT1 expression decreases metastasis. Mechanistically, β-catenin and N-cadherin expression is reduced as a result of NEAT1 suppression, while the expression of E-cadherin increased [54] . Research from Jiang et al. showed that BANCR lncRNA promotes breast cancer metastasis through regulating matrix metallopeptidase 2/9 (MMP2/9) and vimentin, EMT markers [55] . lncRNA-ATB (long noncoding RNA activated by TGFβ) has been shown to be upregulated in breast cancer, and increases invasion, metastasis, and involved in resistance to trastuzumab. Moreover, overexpression of lncRNA-ATB is correlated with the expression of ZEB1 (zinc finger E-box binding homeobox 1) and zinc finger protein 217 that promotes EMT and metastasis [56] . Linc-POR lncRNA is overexpressed in breast cancer tissues. The ectopic expression of linc-POR resulted in EMT induction and increased invasion of breast cancer cells, whereas its silencing reduced metastasis of breast cancer cells. Mechanistically, Linc-POR blocks the degradation of miR-205 target gene ZEB2 [57] . lncRNA LINC-00673 is overexpressed in breast cancer, and its overexpression is correlated with lymph node metastasis. Knockdown of LINC00673 suppressed proliferation, invasion, and metastasis in breast cancer cells. Mechanistically, downregulation of LINC00673 reduced the expression of vimentin and Ncadherin, and increased the expression of E-cadherin [58] . lncRNA PVT1 (plasmacytoma variant transcription 1) has been shown to be overexpressed in different types of malignancies including breast cancer, and its elevated level is associated with poor prognosis in breast cancer patients. SOX2 is a TF with a pivotal role in tumorigenesis and binds to the promoter of PVT1 to enhance its transcription. SOX2-mediated overexpression of PVT1 is reported to promote breast cancer invasion by triggering EMT [59] .
Decreased expression of lncRNA-ANCR was reported in breast cancer tissues and cells. Silencing ANCR in MCF-7 cells increases cell migration and invasion, and promotes EMT. EZH2 is an epigenetic factor, is a component of Polycomb repressive complex 2 (PRC2) and promotes EMT. Zhongwei et al. showed that ANCR increased the binding of EZH2 to cyclin dependent kinase 1 (CDK-1), and then CDK1 phosphorylates EZH2 resulting in EZH2 degradation. Altogether, ANCR reduces the invasion and EMT of breast cancer cells through degradation of EZH2 [17] . LINC01638 showed high levels of expression in triple-negative breast cancer (TNBC) tissues, and its overexpression is associated with poor prognosis in breast cancer patients. LINC01638 activated MTDH-Twist1 expression to induce EMT through prevention of SPOPmediated c-Myc ubiquitination and degradation [60] . Different mechanisms mediated by lncRNAs promoting invasion and metastasis in breast cancer are summarized in Fig. 5 and Table 2 . In summary, these reports indicate lncRNAs play a significant role in regulating EMT.
lncRNAs enhance invasion and metastasis through regulation of miRNAs lncRNA-NNT-AS1 has been shown to be overexpressed in breast cancer. Silencing NNT-AS1 expression by short hairpin RNA (shRNA) reduced proliferation rate, migration, and EMT process in MDA-MB-231 and MCF-7 breast cancer cells. NNT-AS1 facilitates breast cancer metastasis by promoting ZEB1 expression via targeting miR-142-3p [61] . lncRNA-GAS5 is downregulated in TNBC and its downregulation is associated with lymph node metastasis, and the tumor stage. Mechanistically, GAS5 binds to the miR-196A-5p and there is a negative correlation between the expression of GAS5 and miR-196A-5P. Mechanistically, miR-196a-5p induces invasion and activates FOXO1/PI3K/ AKT signaling pathways in breast cancer cells. GAS5 suppresses triple negative breast cancer progression through binding to miR-196a-5p [62] . In addition, GAS5 can function in a ceRNA-dependent manner through sponging miR-23a. miR-23a has increased expression in breast cancer patients with lymph node metastasis. miR-23a targets ATG3, a member of an autophagy-essential proteins. Thus, GAS5, indirectly, has a positive effect on ATG3 expression, and plays a role in autophagy initiation [63] . lncRNA LINC01116 has been shown to be upregulated in breast cancer tissues, and is associated with tumor stage and lymph node metastasis. By acting as an endogenous sponge LINC01116, it binds directly to miR-145, resulting in the upregulation of estrogen receptor 1, a target gene of miR-145 [64] . lncRNA-SNHG15 is also overexpressed in breast cancer tissues and cell lines, and its silencing results in impaired migration and invasion of breast cancer cells. Mechanistically, SNHG15 sponged miR-211-3p, that can inhibit cell proliferation and migration in breast cancer [65] . lncRNA TP73-AS1 through miR-200a/ZEB1 axis promotes migration and invasion of breast cancer cells. ZEB1, a direct target of miR-200a is an important EMT TF, activates TP73-AS1 expression by binding to its promoter to induce metastasis. It has been shown that TP73-AS1 has increased expression in breast cancer and miR-200a, a direct target of TP73-AS1 [66] . PRLB (progression-associated lncRNA in breast cancer) is also implicated in breast cancer. PRLB is upregulated in breast cancer tissues and cell lines and its overexpression is correlated with metastasis. PRLB is involved in breast cancer progression and chemoresistance by serving as a ceRNA, sponging miR-4766-5p, and therefore modulates the expression of miR-4766-5p target, SIRT1 (sirtuin 1). Accordingly, PRLB is considered as a promising target in the prognosis and treatment of breast cancer [67] .
lncRNA MIAT (Myocardial infarction associated transcript) has been shown to be overexpressed in breast tumor tissues. MIAT level is much higher in advanced breast tumors than in the low-grade ones. MIAT knockdown suppresses cell migration and invasion and promotes apoptosis. MIAT silencing is followed by increase in miR-302 and miR-150 and decrease in miR-29c expression [68] . Mechanistically, MIAT functions as a ceRNA by sponging miR-155-5p, and positively regulating DUSP7 (a cytosolic MKP) expression in breast cancer patients [69] . In conclusion, one mechanism of lncRNAs regulation of cancer is through miRNAs.
lncRNAs induce invasion and metastasis via upregulating PI3K-AKT kinase pathway MALAT1 regulates cell migration and motility in breast cancer tissues and cell lines. knockdown of MALAT1 led to metastasis and EMT through the activation of the PI3K-AKT kinase pathway in breast cancer [34] . In addition, MEG3 is downregulated in many types of cancers, including breast cancer. Zhang et al. reported that MEG3 is decreased in breast cancer tissues and cell lines. They also showed that MEG3 overexpression inhibited invasion and angiogenesis in vitro and in vivo, and suppressed breast cancer tumorigenesis through downregulation of the PI3K/ AKT pathway [70] .
lncRNAs promote invasion and metastasis via modulating cell cycle and apoptotic pathways lncRNA-TUG1 (Taurine-upregulated gene 1) is downregulated in breast cancer tissues and cell lines compared with normal counterparts. Decreased expression of TUG1 correlates with lymph node metastasis. Induction of TUG-1 expression inhibited cell migration and invasion through modulating the expression of cell cycle regulators including cyclin D1 and CDK4, and promoting apoptosis in breast cancer cells [71] . LINC00628 inhibits metastasis and promotes apoptosis of MCF-7 breast cancer cells. The relative expression of LINC00628 in breast cancer tissues and cell lines is low, and its low expression is correlated with poor prognosis and overall survival. LINC00628 hampered metastasis through inducing cell cycle arrest at G0/G1 phase and inducing apoptosis in breast cancer cells. In addition, this lncRNA increases expression of Caspase-3 and Bax protein and decreases the expression of Bcl-2 [72] . Nonhomologous end-joining pathway 1 (LINP1) is an oncogenic lncRNA in breast cancer, and it promotes metastasis and chemoresistance in breast cancer. Knockdown of LINP1 suppresses tumor growth through inducing cell cycle arrest in G1 phase and induction of apoptosis [73] . Linc-ITGB1 lncRNA promotes breast cancer progression, and its elevated level is significantly associated with TNM stage and lymph node metastasis [74] . In vitro and in vivo evidence showed that linc-ITGB1 promotes breast cancer progression by inducing cell cycle key regulators such as Cdc25c and Cyclin B1 as well as through the EMT pathway [75] . LincIN lncRNA has been reported to be overexpressed in advanced-stage breast tumors and its elevated level is strongly associated with overall survival in breast cancer patients. LincIN negatively regulates p21 expression at the translational level. High levels of p21 is associated with low metastatic phenotypes in breast cancer and thus, lincIN is considered as a novel metastasisassociated prognostic biomarker for breast cancer [76] .
lncRNAs that regulate invasion and metastasis via MMPs and cell adhesion molecules
HULC (highly upregulated in liver cancer) lncRNA expression is increased in TNBC tissues and cell lines. HULC increased expression is associated with poor prognosis and enhanced metastatic phenotype in TNBC patients. HULC regulates metastasis in TNBC cells via MMP-2 and MMP9 [77] . Recently, Wang et al. showed that SNHG12 is upregulated in TNBC, and its elevated expression is correlated with tumor size and lymph node metastasis. Mechanistically, SNHG12 can promote cell migration by regulating MMP13 expression [78] . lncRNA SKAI1BC functions as a suppressor of KAI expression in breast cancer and is over expressed in TNBC cells. KAI is a tumor and metastasis suppressor in breast cancer. Knockdown of SKAI1BC increased KAI expression which lead to increased cell adhesion and reduced cell invasion and migration. Thus, targeting SKAI1BC might be a potential therapeutic approach in KAI-deficient breast tumors [79] .
Other important metastatic signaling pathways regulated by lncRNAs CCAT2 lncRNA promotes tumor progression and metastasis in breast cancer, and is highly expressed in breast cancer. Moreover, the expression of CCAT2 is reduced in non-metastatic cells compared with metastatic ones. Downregulation of CCAT2 is correlated with cell cycle arrest and induction of apoptosis. In addition, downregulation of CCAT2 leads to reduced expression of the TGF-β signaling pathway components including TGF-β, Smad2 and α-SMA. Thus, CCAT2 enhances breast cancer invasion and metastasis through the TGF-β Signaling pathway [80] . lncRNA EZR-AS1, a member of the ezrin-radixin-moesin family is shown to be overexpressed in breast cancer tissues and is correlated with metastasis. Moreover, knockdown of EZR-AS1 reduces migration and invasion of breast cancer cells by inactivating Wnt/B-catenin pathway [81] . Interestingly, lncRNA-dependent Hippo-YAP signaling has been shown for breast cancer bone metastasis. Crosstalk between ROR1-HER3 and the Hippo-YAP pathway promotes bone metastasis in a MAYA lncRNA-dependent fashion. This study showed that ROR1 phosphorylates HER3, which consequently recruits a RNAprotein complex consists of MAYA, which in turn results in the activation of Yes-associated protein (YAP) [82] . CTD-2108O9.1 lncRNA is a metastatic inhibitor of breast cancer that has low levels of expression in breast cancer tissues and cell lines. CTD-2108O9.1 is involved in the repression of breast cancer metastasis via modulating LIFR (leukemia inhibitory factor receptor). LIFR is designated as a metastasis suppressor in breast cancer [83] . Collectively, all these reports indicate that lncRNAs regulate cancer progression through various signaling mechanisms including PI3K/ AKT, cell cycle, apoptosis and MMP pathways.
lncRNAs as potential prognostic biomarkers in breast cancer
Expression of CCAT1 lncRNA is increased in different types of cancers, especially it is highly overexpressed in breast cancer tissues and its upregulation is associated with tumor differentiation, TNM stage and lymph node metastasis. These findings suggest that CCAT1 can be a novel prognostic biomarker for breast cancer progression [84] . EGOT lncRNA (eosinophil granule ontogeny transcript) expression is reported to be decreased in breast cancer tissues and its lower expression levels are associated with larger tumor size, lymph node metastasis and poor prognosis in the patients. Thus, EGOT can be a potential prognostic marker for breast cancer [85] . DSCAM antisense RNA 1 (DSCAM-AS1) lncRNA is a mediator of breast tumor progression and tamoxifen resistance, and can be considered as a potential clinical target for the treatment of breast cancer [86] . Furthermore, FGF14-AS2 (FGF14 antisense RNA 2) is a tumor suppressor lncRNA in breast cancer. The expression of FGF14-AS2 is negatively correlated with metastasis and advanced stages in breast cancer. Therefore, FGF14-AS2 may be a good prognostic marker in detecting breast cancer [87] . Thus, lncRNAs can serve as diagnostic/prognostic markers of breast cancer.
lncRNAs mechanisms in promoting drug resistance in breast cancer lncRNAs have also been shown to be involved in drugresistance chiefly through altering the gene expression pattern [88] . lncRNA-ATB is activated by TGF-β and induces trastuzumab resistance in breast cancer cells by upregulating ZEB1 and ZNF-217 and competitively binding miR-200c to induce EMT [56] . lncRNA H19 is one of the downstream molecules of ERα in breast cancer cells. In estrogen receptor (ER)-positive breast cancer cells, H19 decreases apoptotic response and promotes paclitaxel resistance by inhibiting transcription of BIK and NOXA. H19 inhibits BIK protein in an epigenetic EZH2-dependent manner [89] . Long noncoding RNA-ROR (lncRNA-ROR) promotes tamoxifen resistance of breast cancer cells. Downregulating lncRNA-ROR inhibits EMT of breast cancer cells and increases the response to tamoxifen by increasing miR-205 expression and suppressing the expression of ZEB1 and ZEB2 [90] . Li et al. have shown that Urothelial carcinoma associated 1 lncRNA (UCA1) promotes tamoxifen resistance in ER-positive breast cancer cells in a hypoxia-inducible factor (HIF)-1-dependent manner. Increased levels of lncRNA UCA1 sponged miR-18a, which is a negative regulator of HIF1α. Altogether, this study showed that the upregulation of UCA1 and downregulation of miR-18a results in tamoxifen resistance in ERpositive breast cancer cells. Furthermore, they showed that miR-18a is a modulator of tamoxifen sensitivity by decreasing Cdc42 expression and increasing p53 expression [91] . One other mechanism, UCA1 confers tamoxifen resistance to breast cancer cells is through the activation of the mTOR signaling pathway [92] . lncRNA of luminal, a novel lncRNA found to be associated with tamoxifen resistance by sponging let-7 miRNAs [93] . One major obstacle in clinical management of HER2-positive breast cancer is the resistance to trastuzumab. Li et al. have shown that downregulation of GAS5 causes trastuzumab resistance in breast cancer cells. Mechanistically, GAS5 functions as a molecular sponge for miR-21, increasing phosphatase and tensin homolog pseudogene (PTEN) expression [94] . lncRNA BCAR4 is associated with tamoxifen resistance in breast tumors by activation of the ERBB2/ERBB3 signaling pathway [95] . Furthermore, BCAR4 induces anti-estrogen resistance through binding to and activating the TFs SNIP1 and PNUTS, and consequently activating the hedgehog/ GLI2 transcriptional program [44] . In breast cancer cells lncRNA PANDA induces doxorubicin resistance by interacting with the TF NF-YA and decreasing the expression of proapoptotic genes [96] . Furthermore, HOTAIR depletion significantly decreases tamoxifen resistance in breast cancer cells. HOTAIR is directly inhibited by ER and its upregulation induces ligand-independent ER activities which result in tamoxifen resistance [97] . In a recent study, Wang et al. showed that the lncRNA linc00518 contributes to promoting multidrug resistance in breast cancer cells through the regulation of the miR-199a/MRP1 axis [98] . In addition, it has been shown that lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) upregulation is correlated with paclitaxel resistance in breast cancer tissue samples and cells. Mechanistically, FTH1P3 acts as a ceRNA to sponge miR-206 and increase ABCB1 protein expression [99] . All these reports clearly state that lncRNAs play a major role in developing drug resistance through various pathways. lncRNAs mechanisms in promoting drug resistance in breast cancer are summarized in Table 3 .
lncRNAs regulation of metabolic reprograming in breast cancer
Metabolic pathway reprogramming is one of the main features of cancer cells. lncRNAs, play key roles in displaying distinct metabolic behavior in tumor cells through modulating metabolic enzymes, regulating glycolysis, amino acid and lipid metabolism. lncRNAs are also capable of regulating signaling pathways such as the PI3K/AKT/ mTOR pathway which has a great potential to affect cellular metabolism in favor of tumor progression [100] . lncRNAH19 is upregulated in breast cancer tissues and induces stem cell maintenance and migration ability of breast cancer cells. H19 acts as a ceRNA which increases expression of LIN28, an essential stem cell factor that has high levels in breast cancer stem cells (BCSCs) and patient samples [101] . lncRNA LINC00538 (YIYA) has been shown to be upregulated in breast cancer cells and enhances glycolysis and tumor progression. YIYA modulates CDK6 and fructose bisphosphatase phosphorylation, which in turn induces glycolysis by converting glucose 6-phosphate to fructose-2,6-bisphosphate/fructose-1,6-bisphosphate [102] .
Recently, Peng et al. showed that the lncRNA H19 is associated with high rate of glycolysis and preservation of BCSC features in pyruvate dehydrogenase kinase 1 (PDK1)-enriched BCSCs. In addition, in vitro and in vivo data indicate that inhibition of H19 diminishes the PDK1 expression level during hypoxia which results in glycolysis reduction and lower self-renewal ability in breast cancer cells [103] . It is also possible that lncRNAs regulate glycolysis in normoxic condition. lincRNA for kinase activation triggers the phosphorylation of HIF1α through recruitment of breast tumor kinase (BRK) to EGFR:GPNMB heterodimer complex and BRK kinase activation, which finally results in stabilization of HIF1α in normoxic condition to further progress breast cancer development by enhancing glycolysis [104] . FGF13-AS1 downregulation is associated with poor prognosis in breast cancer. FGF13-AS1 suppresses breast cancer metastasis by blocking glycolysis and stemness characteristics of breast cancer cells. Mechanistically, FGF13-AS1 decreases Myc mRNA stability, and disrupts the interaction between Myc mRNA and insulin-like growth factor-2 mRNA binding proteins [105] . In sum, lncRNAs regulate cancer progression through various metabolic signaling pathways as well.
Role of lncRNAs in different subtypes of breast cancer
Numerous studies showed the role of lncRNAs in different subtypes of breast cancer. LncRNAs may play important roles in breast cancer heterogenicity as well [106] . HER2positive breast cancer is determined as a distinct subtype of breast cancer and is associated with poor prognosis. Wang and colleagues showed that the expression of lncRNA HOTAIR in circulatory exosomes was significantly higher in MCF-7/HER2 cells than in the parental MCF-7 cells [107] . A recent study suggested that lncRNA ES3 is upregulated in HER2-positive breast tumors, and that ES3 expression is suppressed when HER2 is being blocked by lapatinib [108] . Studies on mTOR-associated lncRNAs showed that the higher expression of lncRNA SNHG3 in HER2-positive tumors [109] . Moreover, exosomal lncRNA small nucleolar RNA host gene 14 (SNHG14) was upregulated in HER2-positive breast cancer patients that are trastuzumab-resistant compared with treatment-responsive patients. This study also demonstrated that knockdown of SNHG14 effectively increased the trastuzumab-mediated cytotoxicity in SKBR-3 and BT474 cell lines [110] . Evaluating the lncRNA TUG1 expression in HER2-positive subtypes showed elevated TUG1 in HER-2-positive patients compared with luminal A. Gradia et al. also found that TUG1 has a different impact on patients' survival. Although low expression of TUG1 is correlated with improved disease-free survival in HER2-positive patients, higher expression of TUG1 is correlated with increased disease-free survival in luminal B patients [111] . lncRNA DRAIC is upregulated in ER/PR-positive patients compared with their negative ones. Zhao et al. found that DRAIC is upregulated in lapatinib-sensitive breast cancer cell lines compared with lapatinib-resistant cell lines. Also, DRAIC exhibited a high expression levels in patients that are resistant to paclitaxel and FEC (F, fluorouracil; E, epirubicin hydrochloride; C, cyclophosphamide) [112] . In 2019, Li et al. revealed that lncRNA LincK is correlated with breast tumorigenesis in both MCF-7 and MDA-MB-231 cells by promoting proliferation and EMT [113] . Altogether, different expression profiles of lncRNAs may be used to distinguish different subtypes and they can be used as prognosis and diagnosis biomarkers in different subtypes.
lncRNAs regulate breast cancer stemness
BCSCs, are small subpopulation of tumor cells with the ability of self-renewal and are considered as a source of heterogeneity of the primary tumor. BCSCs play key roles By sponging miR-18a and consequently increasing the expression of HIF-1alpha, a target for miR-18a in ER-positive breast cancer cells UCA1 also promotes tamoxifen resistance via regulating mTOR signaling pathway [91, 92] GAS5 Trastuzumab PTEN Downregulation of GAS5 is associated with trastuzumab resistance [94] BCAR4 Tamoxifen SNIP1 and PNUTS By activating ERBB2/ERBB3 signaling Secondly, through interacting with SNIP1 and PNUTS, and subsequently activation of Hedgehog/GLI2 transcription program [44] PANDA Doxorubicin NF-YA Through interaction with the transcription factor NF-YA and reducing the expression of proapoptotic genes [96] HOTAIR Tamoxifen Via inducing ligand-independent ER activation [97] Linc00518
Multi drug Through regulating miR-199a/MRP1 axis [98] lncRNA FTH1P3 Paclitaxel ABCB1 By sponging miR-206 and activation of ABCB1 [99] LOL Tamoxifen Via sponging Let7 [93] in breast cancer metastasis and drug resistance due to their stem cell characteristics [114] . lncRNAs can initiate or sustain stem-cell phenotypes directly or indirectly through activation of TFs including SOX2, OCT4, KLF4, and NANOG [115] [116] [117] . For instance, lncRNA ES1, a downstream target for stem cell promoting TFs Oct4 and Nanog is shown to be overexpressed in high-grade and P53mutated breast cancer tissues. Silencing of ES1 resulted in the induction of apoptosis, cellular senescence and cell cycle arrest. Mechanistically, ES1 regulates the proliferation and death of breast cancer cells by regulating the OCT4 and SOX2 expression through miR-302/miR-106b axis [118] . Moreover, lncRNA NEAT1 is overexpressed in breast cancer samples and silencing of NEAT reduces the stem cell population and rescued the sensitivity of TNBC cells to chemotherapy in TNBC cells [119] . Another mechanism utilizing lncRNAs to modulate the stemness of breast cancer cells is through miRNAs, mainly by functioning as ceRNA. For example H19 functions as a sponge for Let7c resulted in activation of the Wnt signaling pathway-that regulates the symmetric division of BCSCs, which in turn results in promoting self-renewing capacity of the cells [120] . Moreover, H19 acts as a ceRNA for miRNA let-7 to increase the HIF 1α and enhances Expression of PDK1 expression induces stem-like phenotypes in breast cancer cells [103] . Similarly, LINC00511 is upregulated in breast cancer and this upregulation is correlated with poor prognosis of the patients. Mechanistically, LINC00511, acts as a ceRNA for miR-185-3p that promotes E2F1 protein leading to increase in stem cell markers and ability of formation spheres [121] . In addition, Zheng et al. showed that LUCAT1 enhances Wnt/β-catenin pathway through binding of miR-5582-3p with TCF7L2 and promotes stem cellphenotypes of BCSCs [122] . Interestingly, lncRNAs can also be regulated by tumor microenvironment. For example, mesenchymal stem/stromal cells (MSCs) induces LINC01133 to promote cancer-stem cell-like characteristics of neighboring TNBC cells microenvironment through the upregulation of KLF4 [117] . Aldehyde dehydrogenase 1A3 increases the stem cell phenotypes of TNBC cells through lncRNA NRAD1 [123] . In Twist-positive breast cancer cells, it is shown that lncRNA-Hh activates hedgehog signaling to promote the expression of stem cell factors SOX2 and OCT4 [124] . Collectively, this evidence indicates insights and novel molecular mechanisms by which lncRNAs promote BCSC phenotypes.
Exosomal lncRNAs
Exosomes are critical cellular connectors containing a variety of proteins and nucleic acids including miRNAs and lncRNAs, and they participate in many cellular functions [125, 126] . Accumulating evidence indicated that signals transmitted by exosomal lncRNAs regulate many types of local and distant recipient cells. Moreover, there are differences in levels and types of exosome-mediated transferring pathways of lncRNAs in normal physiological situations and pathological conditions such as cancer. Loading of certain lncRNAs into exosomes occurs selectively; however, the packaging mechanisms remain poorly understood. Also the abundance of exosomal lncRNAs correlates with their expression level in the cell of origin [127] . Koldemir et al. showed that cellular expression of lncRNA GAS5 in breast cancer cells leads to its exosomal enrichment which is considered as a marker of apoptotic induction [128] . Interestingly, lncRNAs can trigger exosome secretion pathways that result in cancer progression. Overexpression of lncRNA HOTAIR in HCC has a direct relationship with the multi vesicular body (MVB) transport to the plasma membrane. Mechanistically, HOTAIR regulates expression and localization of RAB35 and influences the localization of proteins of the fusion process, and contributes to MVBs docking with the plasma membrane [129, 130] . Interestingly, tumor-derived exosome contents reflect the changes in the tumor cells during different stages of cancer progression such as neoangiogenesis, premetastatic niche formation and drug resistance behavior of tumors [125] . Many studies have revealed that cancer derived exosomal lncRNAs have essential roles in invasion, angiogenesis and drug resistance of tumor cells [131] .
Exosomal lncRNAs roles in cancer cell proliferation, angiogenesis and invasion
Hypoxic condition promotes proliferation, migration and invasive behavior of bladder cancer (BC) cells through increased expression level of exosomal lncRNA-UCA1 [132] . MALAT1 is a well-known lncRNA associated with cancer progression. Exosomal MALAT1 derived from epithelial ovarian cancer (EOC) cells increases proangiogenic activity of endothelial cells and is highly correlated with metastatic phenotype of EOC [133] . Exosomal MALAT1 secreted by breast cancer cells regulate cancer progression through enhanced cell proliferation of recipient cells in tumor microenvironment [134] . Moreover, elevated expression of exosomal MALAT1 in NSCLC cells promotes cell proliferation and migration, and is positively associated with lymph node metastasis [135] . lncRNA-ATB shuttled by glioma cell-derived exosomes activates astrocytes through suppression of miR-204-3p in an Argonaute-2-dependent manner leading to increased invasion of glioma cells [136] . A recent study has shown that tumorderived exosomal lnc-Sox2ot acts as a ceRNA by competitively binding to the miR-200 family to regulate the expression of Sox2 in pancreatic ductal adenocarcinoma (PDAC) and finally promotes EMT, metastasis and stem cell like features of PDAC cells [137] . There is also evidence that angiogenesis initiating factors were increased after culturing human brain microvascular endothelial cells (HBMECs) with linc-POU3F3 containing exosomes. In vitro and in vivo data showed that HBMECs proliferation, migration, and arteriole formation are phenotypic results of the elevated expression of exosomal linc-POU3F3 [138] . Furthermore, increased level of exosomal lncRNA ZFAS1 expression is in parallel with gastric cancer cell migration and lymphatic metastasis [139] .
Exosomal lncRNAs roles in drug resistance
Exosomal lncRNA-SNHG14 promotes trastuzumab resistance in patients with HER2-positive breast cancer. The signal transduction reporter array indicated that the trastuzumab resistance mediated by lncRNA-SNHG14 occurs through the Bcl-2/BAX axis [140] . Moreover, exosomal transfer of lncRNA-UCA1 to tamoxifen-sensitive ERpositive breast cancer cells enhances drug resistance [141] . It has been indicated that exosome-derived LncARSR is highly expressed in sunitinib-resistant RCC cells, increases the expression of AXL/c-MET through binding to miR-34 and miR-449 [142] . Exosomal lnc SBF2-AS1 secreted by temozolomide (TMZ) resistant glioblastoma (GBM) cells promotes resistance behavior of GBM sensitive cells. Mechanistically, TF ZEB1 directly binds to the promoter of SBF2-AS1 to regulate its expression level resulted in TMZ resistance in GBM cells. [143] . Furthermore, lncRNA AGAP2-AS1-containing exosomes enhance trastuzumab resistance in breast cancer cells [144] . These data suggest that exosomes play a significant role in drug resistance.
Exosomal lncRNAs as potential biomarkers and therapeutic agents
Recent studies revealed that exosomal lncRNAs are enriched and more stable in the body fluids, and they are being considered as novel diagnostic and prognostic biomarkers in different types of cancers. For example, exosomal H19, an oncogenic lncRNA detected in the serum and plasma of breast cancer patients, and has considerable value as a predictive cancer biomarker [145] . A recent study demonstrated that upregulated levels of tumor specific lncRNAs SAP30L-AS1 and SChLAP1 in tumor-derived exosomes and thus can be considered as potential biomarkers for prostate cancer [146] . Furthermore, GAS5 expression in circulating exosomes of NSCLC patients is correlated with tumor size and stage. Since patients with early stage of NSCLC showed higher expression level of exosomal GAS5 compared with patients in advanced stage, tumor-derived exosomal GAS5 is considered as a potential biomarker for diagnosis and prognosis of early stages of NSCLC [147] .
Also, it has been reported that tumor-derived exosomal lncRNA SOX2-OT levels are upregulated in lung squamous cell carcinoma (LSCC) patients, and its expression depends on the tumor size, TNM stage and lymph node metastasis, thus SOX2-OT might be a promising tumor biomarker for LSCC [148] . Moreover, exosomal lncRNA CRNDE-h expression levels in colorectal cancer (CRC) are correlated with lymph node metastasis. Accordingly, exosomal CRNDE-h is pondered as a novel serum-based biomarker for CRC [149] . lncRNA HOTAIR has been detected in the urinary exosomes of urothelial bladder cancer (UBC) patients. Loss of HOTAIR expression in UBC cell lines reduces their in vitro migration and invasion, and is an ideal biomarker for UBC [150] . Discovering the therapeutic potential of exosomal lncRNAs can help monitoring cancer progression and reducing its side effects. Interestingly Li et al. showed that transferring of exosomal lncRUNX2-AS1 from multiple myeloma (MM) cells to MSCs repress the osteogenesis through the exosomal lncRUNX2-AS1/ RUNX2 pathway [151] . Conversely, it is also possible to transfer lncRNAs to cancer cells; for example, transferring of exosome-derived lncRNA PTENP1 from normal cells to BC cells suppress the malignant feature of BC cells through decrement of cell invasion and migration and increment of cell apoptosis. Exosomal PTENP1 competitively binds to miRNA-17 and regulates PTEN expression [152] . A recent study revealed that enhanced expression of lncRNA-APC1 inhibits colorectal carcinoma (CRC) cell growth, angiogenesis, and metastasis through direct binding to Rab5b mRNA thus suppressing exosome production. lncRNA-APC1 expression is controlled by APC through PPARα enrichment on lncRNA-APC1 promoter [153] . In conclusion, lncRNAs regulate exosome secretion, which in turn regulates cancer progression.
lncRNA targeted therapy with ASOs and exosome mediated lncRNA/ASO delivery Antisense oligonucleotides (ASOs) are single-stranded synthesized oligonucleotides that target various RNAs such as lncRNAs capable of disrupting RNA splicing or protein complexes and mature RNA formation as well [154] . Recently, ASOs are being considered as therapeutic and druggable strands to target cancer related pathways [155] . Since ncRNAs, such as lncRNAs, have an important role in regulating gene expressions in cancers, ASOs complementary to a ncRNA sequence are used as antagonists to negatively regulate gene expression [156] . Also, knockdown efficiency of the nuclear lncRNAs via ASOs are higher than siRNAs [157] .
Using specific locked nucleic acid (LNA)-enhanced ASOs, Bester et al. suppressed the GAS6-AS2 lncRNA that resulted in enhanced K562 cell sensitivity to cytarabine treatment [158] . Interestingly, it was reported that using two different gapmers (LNA-conjugated chimeric single-strand ASOs) targeting different parts of MALAT1 lead to its knockdown and suppression of cancer progression of MMTV-PyMT mouse mammary carcinoma model [159, 160] . Another study revealed that targeting MALAT1 by novel LNA-gapmer ASO inhibited the expression of proteasome subunit genes and induced apoptotic pathways in MM cells [155] . Suppression of lncRNA UCA1 by short interfering RNAs (siRNAs) or shRNA lead to increased tamoxifen resistance in breast cancer cells [154] . Despite major efforts in identifying promising and functional ASOs, optimization of siRNAs and LNA ASOs for lncRNA targeting is essential because thermal instability and vulnerability to ribonucleases must be validated. Utilization of peptide nucleic acids (PNA) are being considered as a novel cancer therapeutic approach. The first promising report revealed that the application of PNAs in breast cancer to target HOTAIR suppressed MMP-9 and Interleukin 6, and consequently increased sensitivity to platinum-based chemotherapy [161] .
Future progression of ASO therapy not only focuses on defining the best target sequences with higher specificity but also to find better delivery approaches [162] . Although delivery of oligonucleotides remains a critical part of the treatment methods, various ASO transport strategies are being used. The most widely used delivery approach is lipid based [163] . Recently, exosomes are being considered as potential vehicles for new therapeutic delivery approaches. Exosomes can be loaded with therapeutic oligonucleotides to target regulatory RNAs including miRNAs and lncRNAs as independent or combination therapy method to regulate cancer progression [164] . Generally, Exosomes that are used for the therapeutic delivery are prepared from the cell, or can be made through various engineering manipulations. Firstly, exosomes loaded with the cell-selected cargoes can be exploited. Cells can directly become loaded with intended exogenous factors such as proteins, lipids and nucleic acids (mRNAs, miRNAs, lncRNAs, etc) to secrete exosomes containing the considered cargo. Secondly, nucleic acids can be directly loaded into exosomes through different transfection methods including electroporation, sonication, lipofection, or calcium chloride. Collectively, modified exosomes can be delivered to the recipient cells to alter the gene expression [165, 166] . Direct transfection of nucleic acids into exosomes through electroporation or other approaches is not efficient enough as the procedure requires repetitive purification, and also there would be a high probability of extensive exosome aggregation during loading [167, 168] . Thus, active packaging of nucleic acids into exosomes through protein or peptide binding to a specific RNA sequence may increase the efficiency of productive exosome-nucleic acid delivery [167] . A new delivery method for specific RNAs packaging into exosomes has been developed through an active packaging device and a cytosolic transfer assistant. These Exosomal transfer into cells (EXOtic devices) were developed to produce exosomes with specific packed mRNAs to be collected and transferred to the target cells. With these EXOtic devices, there is no need to concentrate exosomes [169] . It is very important to note that selection of the most appropriate type of natural or modified exosomes is necessary, because some exosomes may interact with immune system and affect target destination due to the differential expression of antigen presentation on the exosomes [170] . In a recent study exosomes derived from red blood cells were loaded with anti-miR-125b ASOs through electroporation technique and then transfected to the MOLM13 cells in order to release the suppressed genes in P53 network [171] . Since miR-125b is a well-known oncomiR in chemoresistant breast tumors [172] , the effects of this approach can be used for breast cancer cells and even various lncRNAs can be considered for the targeted therapy through exosome-ASO delivery.
Conclusion
Substantial knowledge on how lncRNAs contribute to cancer has accumulated in the last 10 years and extensive efforts has fostered to discover functional molecular drugs and potential targets for the treatment of breast cancer patients. lncRNAs function as oncogenes and tumor suppressors, and they can serve as good prognostic markers of breast cancer. As expected, targeting oncogenic lncRNAs in patients accompanied with significant challenges that need to be addressed prior to their application in the clinic. Also, lncRNAs that regulate drug resistance can be prospective candidates to develop new targeted therapies. Interestingly, lncRNAs are detected in exosomes as delivery tools in cells. Since several lncRNA expression levels correlate with tumor size and stage, and lncRNA are found in tumor derived exosomes, research linked with the both will have great therapeutic advantages. Thus, further exploring the tumor-derived exosomal lncRNA expression levels, purification and content analysis of tumor derived exosomes provide valuable information on lncRNA-dependent deregulated signaling pathways within cancer cells. Also, exosomes can be recruited as the lncRNA carriers expression to alter the cellular gene expression levels associated with cancer progression. In summary, utilization of exosomes as compatible carriers with different biofluids for well protected delivery of potential tumor suppressor lncRNAs or transfer of ASOs to suppress oncogenic lncRNAs can be considered as new promising approaches for cancer treatment.
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